- Chapter Cover
- Consultation with experts
- Classification of anti-tuberculosis drugs
- Evolving options for DR-TB treatment
- Choosing among regimens for MDR-TB
- Shorter-course (6-month) regimens: BPaL and BPaLM
- Individualized, longer duration (15-24 month) regimens for MDR-TB
- Additional considerations when choosing an MDR-TB regimen
- WHO recommendations for shorter (6 or 9 months) and longer (>18 months) duration DR-TB regimens
- Mono-resistant Mycobacterium (M.) tuberculosis
- Poly-resistant M. tuberculosis
- Extensively drug-resistant M. tuberculosis (XDR-TB)
- When to consider an expanded empiric treatment regimen
- Specific drugs
- Administration of the treatment regimen
- Therapeutic drug monitoring (TDM)
- Role of surgery in the treatment of DR-TB
- Outcomes of treatment
- References